{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:32:08Z","timestamp":1792798328441,"version":"4.5.0"},"reference-count":43,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2008,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Activating mutations of MPL exon 10 have been described in a minority of patients with idiopathic myelofibrosis (IMF) or essential thrombocythemia (ET), but their prevalence and clinical significance are unclear. Here we demonstrate that MPL mutations outside exon 10 are uncommon in platelet cDNA and identify 4 different exon 10 mutations in granulocyte DNA from a retrospective cohort of 200 patients with ET or IMF. Allele-specific polymerase chain reaction was then used to genotype 776 samples from patients with ET entered into the PT-1 studies. MPL mutations were identified in 8.5% of JAK2 V617F\u2212 patients and a single V617F+ patient. Patients carrying the W515K allele had a significantly higher allele burden than did those with the W515L allele, suggesting a functional difference between the 2 variants. Compared with V617F+ ET patients, those with MPL mutations displayed lower hemoglobin and higher platelet levels at diagnosis, higher serum erythropoietin levels, endogenous megakaryocytic but not erythroid colony growth, and reduced bone marrow erythroid and overall cellularity. Compared with V617F\u2212 patients, those with MPL mutations were older with reduced bone marrow cellularity but could not be identified as a discrete clinicopathologic subgroup. MPL mutations lacked prognostic significance with respect to thrombosis, major hemorrhage, myelofibrotic transformation or survival.<\/jats:p>","DOI":"10.1182\/blood-2008-01-131664","type":"journal-article","created":{"date-parts":[[2008,5,4]],"date-time":"2008-05-04T01:35:12Z","timestamp":1209864912000},"page":"141-149","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":361,"title":["MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort"],"prefix":"10.1182","volume":"112","author":[{"given":"Philip A.","family":"Beer","sequence":"first","affiliation":[{"name":"Department of Haematology, University of Cambridge, Cambridge, United Kingdom;"},{"name":"Department of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Campbell","sequence":"additional","affiliation":[{"name":"Department of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom;"},{"name":"Wellcome Trust Sanger Institute, Duxford, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda M.","family":"Scott","sequence":"additional","affiliation":[{"name":"Department of Haematology, University of Cambridge, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony J.","family":"Bench","sequence":"additional","affiliation":[{"name":"Department of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy N.","family":"Erber","sequence":"additional","affiliation":[{"name":"Department of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bareford","sequence":"additional","affiliation":[{"name":"Department of Haematology, Russell's Hall Hospital, Dudley, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget S.","family":"Wilkins","sequence":"additional","affiliation":[{"name":"Department of Pathology, Royal Victoria Infirmary, Newcastle, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John T.","family":"Reilly","sequence":"additional","affiliation":[{"name":"Department of Haematology, Royal Hallamshire Hospital, Sheffield, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans C.","family":"Hasselbalch","sequence":"additional","affiliation":[{"name":"Department of Haematology and Pathology, Odense University Hospital, Odense, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bowman","sequence":"additional","affiliation":[{"name":"Medical Research Council (MRC) Dunn Nutrition Unit, University of Cambridge, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Wheatley","sequence":"additional","affiliation":[{"name":"Birmingham Clinical Trials Unit, Birmingham, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Buck","sequence":"additional","affiliation":[{"name":"Clinical Trials Service Unit, Oxford, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire N.","family":"Harrison","sequence":"additional","affiliation":[{"name":"Department of Haematology, St Thomas's Hospital, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony R.","family":"Green","sequence":"additional","affiliation":[{"name":"Department of Haematology, University of Cambridge, Cambridge, United Kingdom;"},{"name":"Department of Haematology, Addenbrooke's Hospital, Cambridge, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111712415980500_B1","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1056\/NEJM197610212951702","article-title":"Polycythemia vera: stem-cell and probable clonal origin of the disease.","volume":"295","author":"Adamson","year":"1976","journal-title":"N Engl J Med"},{"key":"2019111712415980500_B2","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"2019111712415980500_B3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"2019111712415980500_B4","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"2019111712415980500_B5","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders.","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111712415980500_B6","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"2019111712415980500_B7","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2007.06806.x","article-title":"Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera.","volume":"139","author":"Scott","year":"2007","journal-title":"Br J Haematol"},{"key":"2019111712415980500_B8","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1182\/blood-2007-07-101576","article-title":"Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders.","volume":"111","author":"Pietra","year":"2008","journal-title":"Blood"},{"key":"2019111712415980500_B9","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","article-title":"Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.","volume":"366","author":"Campbell","year":"2005","journal-title":"Lancet"},{"key":"2019111712415980500_B10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.10634","article-title":"Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status.","volume":"92","author":"Finazzi","year":"2007","journal-title":"Haematologica"},{"key":"2019111712415980500_B11","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood-2006-12-064287","article-title":"Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia.","volume":"110","author":"Vannucchi","year":"2007","journal-title":"Blood"},{"key":"2019111712415980500_B12","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.22663","article-title":"Clinical correlates of JAK2V617F allele burden in essential thrombocythemia.","volume":"109","author":"Kittur","year":"2007","journal-title":"Cancer"},{"key":"2019111712415980500_B13","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1182\/blood-2005-08-3395","article-title":"V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis.","volume":"107","author":"Campbell","year":"2006","journal-title":"Blood"},{"key":"2019111712415980500_B14","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1182\/blood-2007-07-099184","article-title":"JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.","volume":"110","author":"Barosi","year":"2007","journal-title":"Blood"},{"key":"2019111712415980500_B15","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/j.leukres.2006.01.008","article-title":"JAK2(V617F) and leukemic transformation in myelofibrosis with myeloid metaplasia.","volume":"30","author":"Mesa","year":"2006","journal-title":"Leuk Res"},{"key":"2019111712415980500_B16","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia.","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"2019111712415980500_B17","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"2019111712415980500_B18","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1182\/blood-2005-06-2600","article-title":"An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor.","volume":"107","author":"Staerk","year":"2006","journal-title":"Blood"},{"key":"2019111712415980500_B19","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","article-title":"Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.","volume":"137","author":"Guglielmelli","year":"2007","journal-title":"Br J Haematol"},{"key":"2019111712415980500_B20","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with essential thrombocythemia: a final report on diagnostic criteria, survival, and leukemic transition by treatment.","volume":"34","author":"Murphy","year":"1997","journal-title":"Semin Hematol"},{"key":"2019111712415980500_B21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa043800","article-title":"Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.","volume":"353","author":"Harrison","year":"2005","journal-title":"N Engl J Med"},{"key":"2019111712415980500_B22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1182\/blood-2007-05-091850","article-title":"Bone marrow pathology in essential thrombocythemia: inter-observer reliability and utility for identifying disease subtypes.","volume":"111","author":"Wilkins","year":"2008","journal-title":"Blood"},{"key":"2019111712415980500_B23","doi-asserted-by":"crossref","first-page":"4198","DOI":"10.1182\/blood-2003-10-3471","article-title":"Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin.","volume":"103","author":"Ding","year":"2004","journal-title":"Blood"},{"key":"2019111712415980500_B24","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","article-title":"The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.","volume":"108","author":"Lippert","year":"2006","journal-title":"Blood"},{"key":"2019111712415980500_B25","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1182\/blood-2007-05-089003","article-title":"Evidence for MPL W515L\/K mutations in hematopoietic stem cells in primitive myelofibrosis.","volume":"110","author":"Chalign\u00e9","year":"2007","journal-title":"Blood"},{"key":"2019111712415980500_B26","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1634\/stemcells.2007-0175","article-title":"Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.","volume":"25","author":"Pardanani","year":"2007","journal-title":"Stem Cells"},{"key":"2019111712415980500_B27","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.1182\/blood-2006-04-018259","article-title":"Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.","volume":"108","author":"Scott","year":"2006","journal-title":"Blood"},{"key":"2019111712415980500_B28","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1182\/blood.V93.1.125","article-title":"Autonomous megakaryocyte growth in essential thrombocythemia and idiopathic myelofibrosis is not related to a c-mpl mutation or to an autocrine stimulation by Mpl-L.","volume":"93","author":"Taksin","year":"1999","journal-title":"Blood"},{"key":"2019111712415980500_B29","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/pbc.20185","article-title":"Normal thrombopoietin and its receptor (c-mpl) genes in children with essential thrombocythemia.","volume":"44","author":"Randi","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"2019111712415980500_B30","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1016\/j.exphem.2007.08.010","article-title":"Phenotypic variations and new mutations in JAK2 V617F-negative polycythemia vera, erythrocytosis, and idiopathic myelofibrosis.","volume":"35","author":"Williams","year":"2007","journal-title":"Exp Hematol"},{"key":"2019111712415980500_B31","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1200\/JCO.2006.08.6884","article-title":"Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia.","volume":"25","author":"Teofili","year":"2007","journal-title":"J Clin Oncol"},{"key":"2019111712415980500_B32","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder.","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2019111712415980500_B33","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1046\/j.1365-2141.1997.d01-2042.x","article-title":"A new c-kit mutation in a case of aggressive mast cell disease.","volume":"96","author":"Pignon","year":"1997","journal-title":"Br J Haematol"},{"key":"2019111712415980500_B34","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/1209","article-title":"Familial gastrointestinal stromal tumours with germline mutation of the KIT gene.","volume":"19","author":"Nishida","year":"1998","journal-title":"Nat Genet"},{"key":"2019111712415980500_B35","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/1097-0142(20010801)92:3<657::AID-CNCR1367>3.0.CO;2-D","article-title":"Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa.","volume":"92","author":"Beghini","year":"2001","journal-title":"Cancer"},{"key":"2019111712415980500_B36","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib.","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"2019111712415980500_B37","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/1078-0432.CCR-03-0110","article-title":"Pleomorphic characteristics of a germ-line KIT mutation in a large kindred with gastrointestinal stromal tumors, hyperpigmentation, and dysphagia.","volume":"10","author":"Robson","year":"2004","journal-title":"Clin Cancer Res"},{"key":"2019111712415980500_B38","doi-asserted-by":"crossref","first-page":"e88","DOI":"10.1136\/jmg.2003.015156","article-title":"A germline mutation in KIT in familial diffuse cutaneous mastocytosis.","volume":"41","author":"Tang","year":"2004","journal-title":"J Med Genet"},{"key":"2019111712415980500_B39","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1053\/j.gastro.2005.06.060","article-title":"Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis.","volume":"129","author":"Hartmann","year":"2005","journal-title":"Gastroenterology"},{"key":"2019111712415980500_B40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/ajmg.a.30388","article-title":"Novel c-KIT germline mutation in a family with gastrointestinal stromal tumors and cutaneous hyperpigmentation.","volume":"132","author":"Carballo","year":"2005","journal-title":"Am J Med Genet A"},{"key":"2019111712415980500_B41","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.leukres.2005.08.015","article-title":"A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy.","volume":"30","author":"Zhang","year":"2006","journal-title":"Leuk Res"},{"key":"2019111712415980500_B42","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V110.11.678.678","article-title":"The clinical phenotype of patients with essential thrombocythemia harboring MPL 515W>L\/K mutation.","author":"Vannucchi","year":"2007"},{"key":"2019111712415980500_B43","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders.","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J Med"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/1\/141\/1297780\/zh801308000141.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/112\/1\/141\/1297780\/zh801308000141.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T12:42:11Z","timestamp":1573994531000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/112\/1\/141\/24045\/MPL-mutations-in-myeloproliferative-disorders"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,7,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2008-01-131664","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,1]]}}}